{{drugbox
| IUPAC_name = 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
| image = Lamotrigine.svg
| width = 135
| CAS_number = 84057-84-1
| ATC_prefix = N03
| ATC_suffix = AX09
| ATC_supplemental = 
| PubChem = 3878
| DrugBank = APRD00570
| C=9 | H=7 | Cl=2 | N=5
| molecular_weight = 256.091 g/mol
| smiles = Nc1nnc(c(N)n1)c1cccc(Cl)c1Cl
| bioavailability = 98%
| protein_bound = 55%
| metabolism = Hepatic
| elimination_half-life = 24-34 hours (healthy adults)
| pregnancy_category = C ([[USA|USA]])
| legal_status = N/A([[USA|USA]]); POM ([[United_Kingdom|UK]])
| routes_of_administration = Oral
| excretion = Renal

<!--Clinical data-->
| tradename = Lamictal
| Drugs.com = {{drugs.com|monograph|lamotrigine}}
| MedlinePlus = a695007
| pregnancy_US = C
| pregnancy_AU = D
| legal_AU = S4
| legal_UK = POM
| legal_US = Rx-only
| metabolism = [[Liver|Hepatic]] (mostly [[UGT1A4|UGT1A4]]-mediated)
| elimination_half-life = 24–34 hours (healthy adults)
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| IUPHAR_ligand = 2622
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00555
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3741
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = U3H27498KS
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00354
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 6367
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 741

<!--Chemical data-->
| smiles = Clc2c(Cl)c(c1nnc(nc1N)N)ccc2
| InChI = 1/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PYZRQGJRPPTADH-UHFFFAOYSA-N

}}

'''拉莫三嗪'''（lamotrigine；LTG、嗪/{{lang|en|qín}}）。[[葛蘭素史克|葛蘭素史克]]註冊為'''Lamictal'''，在[[南非|南非]]稱作'''Lamictin'''、[[以色列|以色列]]叫做'''Lamogine'''、在台灣稱作'''樂命達'''、在[[南韓|南韓]]則稱'''라믹탈'''。是一种苯三嗪类的广谱抗癫痫和抗躁鬱症药物，用于治疗[[癫痫|癫痫]]局限性发作的辅助药物。也可以用于稳定[[躁鬱症|躁鬱症]]。[[美国|美国]][[FDA|FDA]]在1998年批准。其半衰期较长（24～30 h），每天可以给药两次。拉莫三嗪的詳細作用機制尚未明瞭，可能是阻斷鈉離子通道。


== 副作用 ==

严重皮肤反应, 例如 [[Stevens–Johnson_syndrome|Stevens–Johnson syndrome]], [[DRESS_syndrome|DRESS syndrome]] 和 [[toxic_epidermal_necrolysis|toxic epidermal necrolysis]].<ref name = "GSKprescribing">{{cite web|url=http://us.gsk.com/products/assets/us_lamictal.pdf|title=Lamictal Prescribing Information|publisher=GlaxoSmithKline.|accessdate=2008-04-09|format=PDF|date=May 2007|archive-url=https://web.archive.org/web/20060913102944/http://us.gsk.com/products/assets/us_lamictal.pdf|archive-date=2006-09-13|dead-url=yes}}</ref> 这些症状几乎全部只在开始使用该药物的第2-8周内出现。一旦发现皮肤异常，病人应该立即寻求医疗帮助，因为这些症状可能是严重副作用的前兆。大约5-10%的病人出疹，其中有千分之一会恶化。据估算大约50,000出疹的人里有1人可能死亡.{{citation needed|date=January 2011}} 儿童比成年人更容易出现皮肤上的副作用。

其它副作用包括发烧，疲劳，失去平衡感, [[diplopia|double vision]], [[strabismus|crossed eyes]], 瞳孔缩小, 视觉模糊, [[眩暈_(醫學)|眩晕]]，嗜睡，[[失眠|失眠]]，焦虑，认知能力下降，情绪不稳，咳嗽，呼吸道堵塞，[[呕吐|呕吐]]，消化不良，腰疼，经期紊乱，痛经等等。副作用症状因人群而异。<ref name="drugs.com">"Lamotrigine Monograph for Professionals"[http://www.drugs.com/monograph/lamotrigine.html] {{Wayback|url=http://www.drugs.com/monograph/lamotrigine.html |date=20190428194908 }},Drugs.com,retrieved Feb.11,2014.</ref>

==化學製劑程序==
拉莫三嗪可從2,3--二氯苯甲酰基氰化物而制得。<ref>
{{US patent|4,560,687}}</ref>
:[[File:Lamotrigine_synth.png|600px]]

== 引用 ==
{{Reflist|2}}

== 外部链接 ==
* [http://www.psycom.net/depression.central.lamotrigine.html FAQ: Psychiatric Uses of Lamotrigine (Lamictal)] {{Wayback|url=http://www.psycom.net/depression.central.lamotrigine.html |date=20210125022234 }}, by Ivan K. Goldberg, MD. Includes many references from the medical literature.
* [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory Center for Drug Evaluation and Research: Lamictal] {{Wayback|url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory |date=20160506041852 }} — documents related to the FDA approval process, including medical reviews and correspondence letters.
* [https://web.archive.org/web/20071227071629/http://www.epilepsy.org.za/faq.php Epilepsy South Africa: MEDICATION FOR EPILEPSY] — an Epilepsy FAQ with a list of medicines for treatment thereof, includes '''Lamotrigine''' with South African trade name '''Lamictin'''.
* [http://www.druglib.com/adverse-reactions_side-effects/lamictal/ Adverse Reactions] {{Wayback|url=http://www.druglib.com/adverse-reactions_side-effects/lamictal/ |date=20130223011534 }} — Reported adverse reactions and side-effects.
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Lamotrigine U.S. National Library of Medicine: Drug Information Portal — Lamotrigine] {{Wayback|url=http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Lamotrigine |date=20131004213953 }}

{{抗癫痫药}}
{{通道阻滞剂}}
{{Sigmaergics}}
{{Mood stabilizers}}
{{GlaxoSmithKline}}

[[Category:抗痉挛药物|Category:抗痉挛药物]]
[[Category:情绪稳定剂|Category:情绪稳定剂]]
[[Category:三嗪|Category:三嗪]]
[[Category:有机氯化合物|Category:有机氯化合物]]